Overview

The Effects of Antihypertensive Agents on Central Blood Pressure in Healthy Participants and Participants With Hypertension (MK-0000-166) (COMPLETED)

Status:
Completed
Trial end date:
2010-11-01
Target enrollment:
0
Participant gender:
All
Summary
This study will test the relationship between CBP (central blood pressure) and PBP (peripheral blood pressure) effects after single and multiple doses of Isosorbide mononitrate extended release (ISMN ER) or Amlodipine besylate in participants with hypertension.
Phase:
Phase 1
Accepts Healthy Volunteers?
Accepts Healthy Volunteers
Details
Lead Sponsor:
Merck Sharp & Dohme Corp.
Treatments:
Amlodipine
Antihypertensive Agents
Criteria
Inclusion Criteria:

- Participant is a male or female between 30 and 65 years of age (inclusive) at the
pre-study (screening)

- Female participant of childbearing potential must have a negative pregnancy test

- Participant has a brachial systolic blood pressure >130 mm Hg

and <180 mm Hg

- Participant has a Body Mass Index (BMI) that is >20 kg/m^2 and <35 kg/m^2

- Participant has been a nonsmoker and/or has not used nicotine or nicotine-containing
products for at least approximately 6 months

Exclusion Criteria:

- Female Participant is pregnant or lactating

- Participant anticipates the use of Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
other than acetaminophen

- Participant is currently a user (including "recreational use") of any illicit drugs,
has a history of drug or alcohol abuse within approximately 2 years, or has a positive
prestudy urine drug screen

- Participant has a condition for which there is a warning, contraindication, or
precaution against the use of ISMN ER including: acute myocardial infarction or
congestive heart failure, hypotension, volume depletion, and pregnancy

- Participant has a history of significant drug allergy or any clinically significant
adverse experience of a serious nature related to the administration of either a
marketed or an investigational drug, including nitrates, nitrites, Amlodipine, and
ISMN ER